Important Note This article is for educational purposes only. BPC-157 is an investigational compound and is not approved for human use in the United Kingdom or most other countries. This content does not constitute medical advice.
BPC-157 was originally derived from a protein found in human gastric juice, which is why much of the early research focused on its potential effects on the digestive system. Researchers have explored whether it may help protect or repair the stomach and intestinal lining in certain experimental models.
This page summarises what current research suggests about BPC-157 in relation to gastrointestinal healing.
Origin and Initial Interest
BPC-157 stands for Body Protection Compound-157. It is a synthetic 15-amino-acid peptide taken from a larger protein naturally present in human gastric juice. Because of this origin, scientists became interested in whether BPC-157 could play a protective role in the gastrointestinal tract, particularly in conditions involving injury or stress to the stomach and intestines.
Areas of Research in Gastrointestinal Healing
Most studies on BPC-157 and the gut have been conducted in animal models. Researchers have investigated its potential effects in several scenarios:
1. Protection Against Stomach Damage Some animal studies have explored whether BPC-157 may help protect the stomach lining from damage caused by irritants or stress. Researchers observed that BPC-157 appeared to reduce the severity of stomach lesions in certain experimental conditions.
2. Intestinal Healing Other studies have looked at BPC-157’s potential effects on intestinal injuries. In some animal models, BPC-157 was associated with improved healing of damaged intestinal tissue and better maintenance of the gut barrier.
3. Effects on Inflammatory Responses in the Gut BPC-157 has also been studied for its possible influence on inflammation in the digestive tract. Some research suggested it may help modulate inflammatory processes, though these findings are still preliminary.
Proposed Mechanisms in the Gut
Researchers have suggested several ways BPC-157 might support gastrointestinal health, including:
- Strengthening the mucosal barrier that protects the stomach and intestines
- Supporting the repair of damaged epithelial cells
- Influencing blood flow and angiogenesis in injured gut tissue
- Modulating inflammatory signalling pathways
These proposed mechanisms are mainly based on animal and cell-based studies. It is still unclear whether these effects would occur in the same way in humans.
Current Limitations
Despite some interesting findings in animal research, there are important limitations:
- Very few high-quality human clinical trials exist.
- Most data comes from short-term animal studies.
- The exact mechanisms of action in the human gastrointestinal tract are not well understood.
- Long-term safety and effectiveness have not been established.
Because of these gaps, BPC-157 cannot currently be considered a proven treatment for any gastrointestinal condition.
Regulatory Status
As of 2026, BPC-157 is not approved by the MHRA or other major regulatory bodies for any medical use, including gastrointestinal conditions. It remains an investigational compound and is not legally available as a medicine in the UK.
Summary
BPC-157 has been studied for its potential protective and healing effects on the gastrointestinal tract, largely because it is derived from a protein found in gastric juice. Some animal studies have suggested it may support the healing of stomach and intestinal injuries and help maintain the gut barrier. However, these findings come mostly from preclinical research. High-quality human clinical trials are very limited, and BPC-157 is not approved for any medical use. More rigorous human studies are needed before any reliable conclusions can be drawn about its effects on gastrointestinal health.
References
- Sikiric, P. et al. (2010). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design.
- Sikiric, P. et al. (2018). BPC 157 and standard angiogenic growth factors in tendon healing. Journal of Orthopaedic Research.
- Krivic, A. et al. (2005). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research.
- ClinicalTrials.gov – Limited human trials registered for BPC-157 as of 2026.
- Medicines and Healthcare products Regulatory Agency (MHRA) – Position on unlicensed substances.
Last Updated: July 2026